KLK3 and pachyonychia congenita: Kawamura et al. reported a five-year bRF survival rate of 97.5% in intermediate-risk PC patients with a T stage of T1c–2b, GS of 7 (3 + 4), and PSA level <10 ng/mL after treatment with high-dose carbon ion radiotherapy alone, and it was not inferior to the corresponding rate of 92.7% in the low-risk group (T stage of T1c–2b, GS≤6, and PSA level <10 ng/mL) [20].